20 Years of TAVI – Achieving comprehensive patient management

Hear leading experts discuss how to adopt a comprehensive and patient-centred management approach in the care of severe aortic stenosis (sAS) patients.

Edwards satellite symposium on comprehensive sAS patient management

At the ESC Congress 2022 – Edwards Lifesciences were proud to partner with leading experts in the field of structural heart disease to host a satellite symposium on ‘20 years of TAVI – How can we get to comprehensive patient management?’

20 years of TAVI – How can we get to a comprehensive patient management? ESC 2022 - 46 min

  • Introduction, purpose and learning objectives by Dr Clare Appleby (00:32)
  • Avoiding common pitfalls, how to accurately diagnose and grade AS by Professor Philippe Pibarot (06:20)
  • Tailored solutions and referral for sAS patients, the importacne of communication and education by Professor Nicole Karam (17:35)
  • Patient anxiety and how to optimally prepare patients for their TAVI procedure by Professor Jan-Malte Sinning (24:47)
  • A panel discussion of the topics covered initiated by Dr Clare Appleby (32:11)

Check our latest articles

View all articles

Stay informed with our newsletter

By providing your personal information, you agree to allow Edwards Lifesciences and its agents to use this information to communicate with you in the future, including information about services, events, and programs. Edwards Lifesciences and its agents will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Edwards Lifesciences and its agents, Edwards Lifesciences will use your information in accordance with the Edwards privacy policy.

Our monthly updates provide you the latest developments in TAVI and aortic stenosis.Read more

AS, aortic stenosis; sAS, severe aortic stenosis; TAVI, transcatheter aortic valve implantation.


1 Edwards data on file.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

PP--EU-5048 v2.0